Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
about
mTOR: from growth signal integration to cancer, diabetes and ageingWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesIdentification of single- and multiple-class specific signature genes from gene expression profiles by group marker indexTargeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorTargeting the translational machinery as a novel treatment strategy for hematologic malignanciesHIV persistence: chemokines and their signalling pathways.Rapalogs in viral cancers.PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.Zebrafish screen identifies novel compound with selective toxicity against leukemia.Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphomaTwo hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.The evolution of the TOR pathway and its role in cancer.Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Upregulation of Nicotinic Acetylcholine Receptor alph4+beta2 through a Ligand-Independent PI3Kbeta Mechanism That Is Enhanced by TNFalpha and the Jak2/p38Mapk Pathways.Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levelsDominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyTargeting the PI3-kinase/Akt/mTOR signaling pathway.Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia.Utility of mTOR inhibition in hematologic malignancies.An overview of the mTOR pathway as a target in cancer therapy.Molecular therapies for tuberous sclerosis and neurofibromatosis.RasGRP Ras guanine nucleotide exchange factors in cancer.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Signaling pathways as therapeutic targets in biliary tract cancer.Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.Acute lymphoblastic leukemia: a comprehensive review and 2017 updateTargeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.
P2860
Q24633662-0DC76ABC-3FF6-4147-B10C-D31442CD5FE9Q26825780-9B64E83B-23C1-4303-9925-37FE936D3E35Q26829652-F81175CD-DB6E-4EED-85A2-DC5FD3E5B787Q28476766-431DE741-1693-4DE1-9163-3EFACB9912D7Q33493174-0300E5D8-030F-4A21-961E-79A25F300302Q33597663-DB32CA26-5246-4037-9000-8D1376A80FAFQ33747291-F22D5AD2-531E-4E79-B34C-A87FC6B2302FQ33774665-49BDEFC0-606C-4B1C-AA36-F067CE3200F1Q34160579-FEC634AF-1A8B-4DF1-9B95-2DCF1D5D3175Q34164683-D0C233C9-4A88-4415-9A99-C5AA7A0B354BQ34227256-46E7CB74-EF2A-4E98-BACF-EB72E51EE1E8Q34255861-DF974527-1621-4273-8055-C5C504ECD73AQ34260622-CE9CBC43-BA97-4027-994A-4A42EDB77F4DQ34307356-EED9FB38-EBF9-4386-B5F0-74273AAB1121Q34318188-010C9FC1-6104-42D7-8A44-2AC27252315AQ34682072-9D2A2970-5272-439F-9302-016439125E2CQ35208383-E81E53C3-8748-4F97-980C-066B1FA12679Q35664310-DC778043-B910-413E-B5FB-F4172CC0FF74Q35679353-5661D852-021B-47EC-A287-5DFFF60E299CQ35855997-BB4BB615-A5F1-4C04-93FD-B56D299CC2ECQ36214162-0F272A2D-1735-4974-ABFB-178801143743Q36339232-C51E951A-B8DA-4412-B9C3-4AFFCDBE1B92Q37192602-DC1725B8-0DD7-4018-A738-04D2FF9CA2AAQ37192611-E7A135BD-17CF-444E-8C02-50495DA3D328Q37192616-AE0A8F38-5238-4E87-BE7E-63D52B157E71Q37265126-763B7020-507F-4CB4-A045-507AB5D0B480Q37779489-FBBDAE0F-9C2E-4EE6-A9BE-9357A23F4FCCQ37861191-07F84D72-A257-48B3-9EF6-021538D860FBQ37883723-829DA5EC-A056-4B48-B953-A2ECDC0F25F2Q38001798-A35C9815-138D-4AC7-AE57-75D9CD2C2AFFQ38006431-A0F4550D-2086-44CB-ADE2-B3C03BB0FCB9Q38205441-2EBF0F85-95AC-410B-85A1-0E5D976753F1Q38218128-8A5B75C6-BB6F-4E0F-9137-3AABFD935DADQ38521775-594657C5-3623-46A4-8231-EAACABE65981Q38747573-D95CAE86-C8D5-4936-B724-73C1C1180341Q38835910-C7B7F3F4-0FD8-4FB1-B4B7-09EEF0FC8DA5Q39344848-DCB7A86A-EE53-4253-A0E8-F730844C9113Q39406969-5460E258-F183-4E42-BDA0-8FCB33026913Q39590044-821F9AA6-AC4A-4249-8705-F1C1AF3A9678Q39653305-58BFB87E-AE0F-481F-B872-059F2C4B4FFF
P2860
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dual inhibition of class IA ph ...... acute lymphoblastic leukemia.
@en
Dual inhibition of class IA ph ...... acute lymphoblastic leukemia.
@nl
type
label
Dual inhibition of class IA ph ...... acute lymphoblastic leukemia.
@en
Dual inhibition of class IA ph ...... acute lymphoblastic leukemia.
@nl
prefLabel
Dual inhibition of class IA ph ...... acute lymphoblastic leukemia.
@en
Dual inhibition of class IA ph ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P1433
P1476
Dual inhibition of class IA ph ...... acute lymphoblastic leukemia.
@en
P2093
Alberto M Martelli
Federica Falà
Francesca Chiarini
Francesca Ricci
Pasqualepaolo Pagliaro
Pier Luigi Tazzari
P2860
P304
P356
10.1158/0008-5472.CAN-08-4884
P407
P577
2009-04-07T00:00:00Z